Darnitsa Group has changed the Head of the Board of Directors

Glib Zagoriy has returned to operational management heading the Board of Directors of the management company Darnitsa Group. This decision was made due to unprecedentedly difficult wartime conditions in which almost all Ukrainian businesses are currently facing.

Dmytro Shymkiv, who has held the post since September 2018, has implemented a number of ambitious objectives. Under his leadership, in particular, “Darnitsa” has been rebranded and transformed into an international company. A full transition to digital management systems has been implemented, the list of pharmaceutical brands has been significantly expanded, etc.

“Transforming the largest pharmaceutical company in the country was a cool challenge from the shareholders. Doing it in the pandemic and war conditions is unique for me as a Manager. I believe that the route we have laid at the intersection of pharmaceuticals and IT all other companies in the industry will now follow. But “Darnitsa” will always be the first,” said Dmytro Shymkiv.

“Darnitsa” would like to thank Dmytro for his four years of tireless work, which helped our company to strengthen its position as the leader of the pharmaceutical industry in Ukraine. Indeed, they were challenging times. However, we have responded with dignity to the challenges of pandemic and war and have become even stronger,” said Glib Zagoriy.

The short-term plans of Darnitsa Group are to continue cooperation with the Ministry of Health and the Ministry of Defense to meet the needs of the state in wartime conditions and fulfil its mission to provide Ukrainians with affordable, modern and effective medicines.

Reference

Glib Zagoriy is a Doctor of Pharmaceutical Sciences, Professor. Since 2019, he has been focused on international direction and development of strategic partnerships of Darnitsa with foreign companies to integrate into the global pharmaceutical market.

PJSC Pharmaceutical Company “Darnitsa” was founded in 1930. Since 1998, the company has been Ukraine’s leader in the production of medicines in volume terms. The strategic areas of portfolio development are cardiology, neurology and pain management. During 2015-2020, “Darnitsa” has launched 134 pharmaceutical brands on the market.